Crossmark Global Holdings’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$53M Sell
44,150
-677
-2% -$692K 0.69% 26
2026
Q1
$41.2M Buy
44,827
+8,318
+23% +$8.43M 0.61% 28
2025
Q4
$39.2M Buy
36,509
+3,821
+12% +$3.65M 0.56% 32
2025
Q3
$24.9M Sell
32,688
-1,008
-3% -$750K 0.37% 58
2025
Q2
$26.3M Buy
33,696
+5,980
+22% +$4.65M 0.42% 49
2025
Q1
$22.9M Buy
27,716
+393
+1% +$327K 0.4% 51
2024
Q4
$21.1M Sell
27,323
-8,787
-24% -$7.28M 0.38% 54
2024
Q3
$32M Sell
36,110
-993
-3% -$893K 0.57% 30
2024
Q2
$33.6M Buy
37,103
+593
+2% +$474K 0.64% 21
2024
Q1
$28.4M Sell
36,510
-612
-2% -$436K 0.54% 27
2023
Q4
$21.6M Sell
37,122
-1,602
-4% -$935K 0.45% 41
2023
Q3
$22.4M Sell
38,724
-370
-0.9% -$191K 0.51% 35
2023
Q2
$17.9M Buy
39,094
+601
+2% +$252K 0.39% 53
2023
Q1
$13.2M Sell
38,493
-15,839
-29% -$5.34M 0.31% 73
2022
Q4
$19.9M Sell
54,332
-6,620
-11% -$2.35M 0.5% 32
2022
Q3
$19.7M Sell
60,952
-735
-1% -$233K 0.55% 28
2022
Q2
$20M Buy
61,687
+3,045
+5% +$914K 0.52% 31
2022
Q1
$16.8M Sell
58,642
-259
-0.4% -$66.7K 0.37% 54
2021
Q4
$16.3M Sell
58,901
-87,108
-60% -$22.1M 0.35% 61
2021
Q3
$33.7M Buy
146,009
+1,010
+0.7% +$249K 0.79% 16
2021
Q2
$33.3M Buy
144,999
+395
+0.3% +$79.3K 0.78% 14
2021
Q1
$27M Sell
144,604
-8,078
-5% -$1.58M 0.67% 20
2020
Q4
$25.8M Buy
152,682
+74,857
+96% +$11.2M 0.65% 22
2020
Q3
$11.5M Sell
77,825
-290
-0.4% -$44.9K 0.32% 70
2020
Q2
$12.8M Buy
78,115
+1,572
+2% +$241K 0.37% 58
2020
Q1
$10.6M Sell
76,543
-4,783
-6% -$657K 0.38% 58
2019
Q4
$10.7M Sell
81,326
-10,283
-11% -$1.19M 0.29% 93
2019
Q3
$10.2M Sell
91,609
-2,941
-3% -$327K 0.3% 86
2019
Q2
$10.5M Sell
94,550
-7,959
-8% -$937K 0.29% 80
2019
Q1
$13.3M Sell
102,509
-3,735
-4% -$454K 0.38% 54
2018
Q4
$12.3M Buy
106,244
+4,427
+4% +$495K 0.38% 56
2018
Q3
$10.9M Sell
101,817
-4,222
-4% -$422K 0.28% 86
2018
Q2
$9.05M Sell
106,039
-4,698
-4% -$386K 0.24% 100
2018
Q1
$8.57M Sell
110,737
-558
-0.5% -$44.9K 0.22% 115
2017
Q4
$9.4M Buy
111,295
+8,112
+8% +$690K 0.23% 107
2017
Q3
$8.83M Buy
+103,183
New +$8.46M 0.23% 107
2016
Q3
$8.83M Buy
+103,183
New +$8.26M 0.23% 107

Other funds holding LLY

Crossmark Global Holdings's LLY Position: Q2 2026 in Review

Crossmark Global Holdings reduced its Eli Lilly (LLY) stake by 1.5% in Q2 2026, selling an estimated $692K and leaving 44,150 shares worth $53M. The position accounts for 0.69% of the portfolio, ranked #26.

Crossmark Global Holdings first reported a position in LLY in Q3 2016 and has held it in 37 quarters since. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Crossmark Global Holdings held 44,150 shares of Eli Lilly worth $53M as of Q2 2026.
  • Crossmark Global Holdings sold 677 Eli Lilly shares in Q2 2026, an estimated $692K.
  • Eli Lilly made up 0.69% of Crossmark Global Holdings's portfolio in Q2 2026, its #26 holding.
  • Crossmark Global Holdings first reported a position in Eli Lilly in Q3 2016 and has held it in 37 quarters since.
  • 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.